SANGAMO THERAPEUTICS INC
SGMO
SGMO was delisted on the 4th of May, 2026.
131 hedge funds and large institutions have $68.2M invested in SANGAMO THERAPEUTICS INC in 2024 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 30 increasing their positions, 50 reducing their positions, and 17 closing their positions.
45% more capital invested
Capital invested by funds: $47.2M → $68.2M (+$21M)
24% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 17
1% more funds holding
Funds holding: 130 → 131 (+1)
0.55% more ownership
Funds ownership: 49.04% → 49.58% (+0.55%)
40% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 50
44% less call options, than puts
Call options by funds: $95K | Put options by funds: $170K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$12.3M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$5.61M |
| 3 |
Mirae Asset Global Investments
Seoul,
South Korea
|
+$358K |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
+$323K |
| 5 |
Goldman Sachs
New York
|
+$270K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$1.17M |
| 2 |
D.E. Shaw & Co
New York
|
-$1.17M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$855K |
| 4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$817K |
| 5 |
BlackRock
New York
|
-$593K |
SGMO Hedge Fund Activity: Q1 2024 in Review
131 of the 6,959 institutional investors tracked by Wall St. Rank reported a position in SANGAMO THERAPEUTICS INC (SGMO) for Q1 2024, worth a combined $68.2M — up 45% from $47.2M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new SGMO positions and 17 closed out — a net gain of 4 holders — while 30 added to existing stakes and 50 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $12.3M. The largest seller was Two Sigma Investments, cutting an estimated $1.17M.
- 131 institutional investors held SANGAMO THERAPEUTICS INC (SGMO) as of Q1 2024, up from 130 in Q4 2023.
- Funds reported $68.2M of SANGAMO THERAPEUTICS INC stock for Q1 2024, up 45% quarter-over-quarter.
- 21 funds opened new SANGAMO THERAPEUTICS INC positions in Q1 2024 and 17 closed out, a net change of +4 holders.
- The largest SANGAMO THERAPEUTICS INC buyer in Q1 2024 was Armistice Capital, an estimated $12.3M added.
- The largest SANGAMO THERAPEUTICS INC seller in Q1 2024 was Two Sigma Investments, an estimated $1.17M sold.
Based on aggregated 13F filings for Q1 2024.